{"id":559692,"date":"2026-06-13T05:00:00","date_gmt":"2026-06-13T03:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/dermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii\/"},"modified":"2026-06-18T17:18:08","modified_gmt":"2026-06-18T15:18:08","slug":"dermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/dermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii\/","title":{"rendered":"Dermatite atopique : des nouvelles int\u00e9ressantes concernant les candidats-m\u00e9dicaments en phase III"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>\u00c0 l&#8217;occasion du congr\u00e8s annuel 2026 de <em>l&#8217;American Academy of Dermatology<\/em> (AAD), des donn\u00e9es d&#8217;\u00e9tude tout juste publi\u00e9es concernant notamment l&#8217;amlitelimab et le rademikibart ont \u00e9t\u00e9 pr\u00e9sent\u00e9es lors de sessions consacr\u00e9es aux derni\u00e8res avanc\u00e9es de la recherche. Les r\u00e9sultats obtenus soulignent le potentiel th\u00e9rapeutique de ces candidats-m\u00e9dicaments : les crit\u00e8res d&#8217;\u00e9valuation cl\u00e9s ont \u00e9t\u00e9 atteints, le profil de s\u00e9curit\u00e9 s&#8217;est r\u00e9v\u00e9l\u00e9 globalement favorable et, \u00e0 l&#8217;instar d&#8217;autres anticorps monoclonaux, l&#8217;amlitelimab et le rademikibart se distinguent par une bonne tol\u00e9rance lors d&#8217;une utilisation \u00e0 long terme.   <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>\u00c0 l&#8217;occasion du congr\u00e8s annuel 2026 de l&#8217;American Academy of Dermatology (AAD), des donn\u00e9es d&#8217;\u00e9tude tout juste publi\u00e9es concernant notamment l&#8217;amlitelimab et le rademikibart ont \u00e9t\u00e9 pr\u00e9sent\u00e9es lors de sessions&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":559693,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Les temps forts du congr\u00e8s annuel de l'AAD","footnotes":""},"category":[11549,11349,11362,11527,11535],"tags":[95013,84938,95129,94822,95128,5437,95132,95130,68912,27675],"powerkit_post_featured":[],"class_list":["post-559692","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-allergologie-et-immunologie-clinique","category-dermatologie-et-venerologie","category-etudes","category-rapports-de-congres","tag-academie-americaine-de-dermatologie","tag-amlitelimab-fr","tag-coast-1","tag-coast-2","tag-congres-annuel-de-laad","tag-dermatite-atopique","tag-radiant-ad","tag-shore","tag-substances-actives-candidates","tag-utilisation-a-long-terme","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-27 05:15:56","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":559695,"slug":"dermatite-atopica-novita-interessanti-sui-principi-attivi-candidati-in-fase-iii","post_title":"Dermatite atopica: novit\u00e0 interessanti sui principi attivi candidati in fase III","href":"https:\/\/medizinonline.com\/it\/dermatite-atopica-novita-interessanti-sui-principi-attivi-candidati-in-fase-iii\/"},"pt_PT":{"locale":"pt_PT","id":559698,"slug":"dermatite-atopica-novidades-interessantes-sobre-candidatos-a-principios-ativos-na-fase-iii","post_title":"Dermatite at\u00f3pica: novidades interessantes sobre candidatos a princ\u00edpios ativos na Fase III","href":"https:\/\/medizinonline.com\/pt-pt\/dermatite-atopica-novidades-interessantes-sobre-candidatos-a-principios-ativos-na-fase-iii\/"},"es_ES":{"locale":"es_ES","id":559684,"slug":"dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii","post_title":"Dermatitis at\u00f3pica: novedades interesantes sobre los candidatos a f\u00e1rmacos en fase III","href":"https:\/\/medizinonline.com\/es\/dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/559692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=559692"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/559692\/revisions"}],"predecessor-version":[{"id":559694,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/559692\/revisions\/559694"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/559693"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=559692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=559692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=559692"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=559692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}